Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added Melanoma as a related topic and linked MedlinePlus Genetics as a related topics resource on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-18T16:46:54.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Removed the older Revision: v3.4.1 and the government funding operating-status notice.
    Difference
    0.4%
    Check dated 2026-02-11T14:08:45.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding lapse notice about the NIH Clinical Center status and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:38:52.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary display option and new QC-related labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with Revision: v3.4.0, while older labels (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4) were removed.
    Difference
    0.3%
    Check dated 2026-01-28T06:34:32.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Added 'Melanoma' as a related topic and included a link to 'MedlinePlus Genetics' in related topics. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-21T05:17:34.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4 and removes Melanoma and related topics such as MedlinePlus Genetics from the related topics section. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-14T03:27:50.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.